Norway Savings Bank decreased its stake in Celgene Corporation (NASDAQ:CELG) by 2.4% during the second quarter, according to its most recent filing with the SEC. The fund owned 4,090 shares of the biopharmaceutical company’s stock after selling 100 shares during the period. Norway Savings Bank’s holdings in Celgene Corporation were worth $531,000 as of its most recent SEC filing.
Other hedge funds have also made changes to their positions in the company. Motco boosted its stake in shares of Celgene Corporation by 306.9% in the first quarter. Motco now owns 822 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 620 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. purchased a new position in Celgene Corporation during the first quarter valued at about $118,000. Carroll Financial Associates Inc. boosted its position in Celgene Corporation by 70.9% in the first quarter. Carroll Financial Associates Inc. now owns 964 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 400 shares in the last quarter. Oakworth Capital Inc. boosted its position in Celgene Corporation by 60.9% in the first quarter. Oakworth Capital Inc. now owns 1,089 shares of the biopharmaceutical company’s stock valued at $136,000 after buying an additional 412 shares in the last quarter. Finally, Acropolis Investment Management LLC purchased a new position in Celgene Corporation during the second quarter valued at about $144,000. Institutional investors own 78.41% of the company’s stock.
Celgene Corporation (NASDAQ CELG) opened at 130.61 on Friday. Celgene Corporation has a 1-year low of $96.93 and a 1-year high of $139.00. The company has a market capitalization of $102.18 billion, a P/E ratio of 40.45 and a beta of 1.89. The firm has a 50-day moving average price of $134.14 and a 200-day moving average price of $124.30.
Celgene Corporation (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.82 EPS for the quarter, topping the consensus estimate of $1.61 by $0.21. The firm had revenue of $3.27 billion during the quarter, compared to the consensus estimate of $3.23 billion. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The company’s quarterly revenue was up 18.7% compared to the same quarter last year. During the same period in the prior year, the business posted $1.44 earnings per share. On average, analysts forecast that Celgene Corporation will post $7.32 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This article was originally published by Community Financial News and is the property of of Community Financial News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://www.com-unik.info/2017/08/12/norway-savings-bank-has-531000-stake-in-celgene-corporation-nasdaqcelg-updated-updated-updated.html.
Several research firms recently issued reports on CELG. Jefferies Group LLC set a $154.00 price target on Celgene Corporation and gave the company a “buy” rating in a report on Saturday, May 13th. BTIG Research cut Celgene Corporation from a “buy” rating to a “neutral” rating and raised their price target for the company from $96.93 to $131.70 in a report on Friday, June 30th. Vetr upgraded Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $148.32 price target on the stock in a report on Thursday. Robert W. Baird reiterated an “outperform” rating and issued a $162.00 price target on shares of Celgene Corporation in a report on Monday, May 22nd. Finally, SunTrust Banks, Inc. set a $150.00 price target on Celgene Corporation and gave the company a “buy” rating in a report on Thursday, July 6th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, twenty-two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $147.00.
In other news, Director Michael D. Casey sold 9,250 shares of the stock in a transaction that occurred on Monday, June 19th. The stock was sold at an average price of $125.59, for a total value of $1,161,707.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Rupert Vessey sold 4,785 shares of the stock in a transaction that occurred on Thursday, June 15th. The stock was sold at an average price of $120.18, for a total value of $575,061.30. Following the completion of the sale, the insider now directly owns 4,004 shares of the company’s stock, valued at $481,200.72. The disclosure for this sale can be found here. Over the last three months, insiders sold 235,255 shares of company stock valued at $31,377,042. Company insiders own 0.95% of the company’s stock.
Celgene Corporation Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
What are top analysts saying about Celgene Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Celgene Corporation and related companies.